<DOC>
	<DOCNO>NCT01056965</DOCNO>
	<brief_summary>The primary objective study obtain preliminary safety tolerability data davunetide ( NAP , AL-108 ) patient tauopathy ( frontotemporal lobar degeneration [ FTLD ] predict tau pathology , corticobasal degeneration syndrome [ CBS ] progressive supranuclear palsy [ PSP ] ) . The secondary objective study obtain preliminary data short term change ( 12 week ) variety clinical , functional biomarker measurement baseline , include cerebrospinal fluid ( CSF ) tau level , eye movement , brain MRI measurement .</brief_summary>
	<brief_title>Davunetide ( AL-108 ) Predicted Tauopathies - Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Aphasia</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Tauopathies</mesh_term>
	<mesh_term>Aphasia , Broca</mesh_term>
	<mesh_term>Primary Progressive Nonfluent Aphasia</mesh_term>
	<criteria>1 . A probable tauopathy define : Probable possible progressive supranuclear palsy ( PSP ) define : 1. least 12month history : postural instability fall first 3 year symptoms present prominent decrease saccade velocity supranuclear ophthalmoplegia ; 2. age symptom onset ≥ 40 year history ; 3. akineticrigid syndrome prominent axial rigidity . OR , Progressive nonfluent aphasia ( PNFA ) define : 1. least 6month history difficulty expressive speech characterize least 3 follow : apraxia speech , speech hesitancy , labor speech , word find difficulty , agrammatism ; 2. symptom subject 's principal neurological deficit symptom constitute initial clinical presentation . OR , Corticobasal Degeneration syndrome ( CBS ) define : 1. least 6month history progressive cortical dysfunction evidence least one following : ideomotor apraxia , alien limb phenomenon , cortical sensory loss , focal asymmetric myoclonus , apraxia speech /nonfluent aphasia ; 2. least 6month history progressive extrapyramidal dysfunction evidence least one following : focal asymmetrical rigidity ( limb axial ) asymmetrical dystonia ( limb axial ) ; lack prominent sustain Ldopa response . OR Frontotemporal Dementia Parkinsonism link Chromosome 17 ( FTDP17 ) : Motor , cognitive behavioral dysfunction , define associate previously demonstrate mutation MAPT gene , meet criteria PNFA , CBS PSP define , CDRFTLD ≥ 1.0 . 2 . Documented age 4085 year time onset symptom associate neurological deficit describe inclusion criterion 1 . 3 . Judged investigator able comply neuropsychological evaluation baseline . 4 . Must reliable caregiver accompany subject study visit . Caregiver must read , understand speak local language fluently order ensure comprehension inform consent form informantbased assessment subject . Caregiver must also frequent contact subject ( least 3 time per week one hour ) willing monitor study medication compliance subject 's health concomitant medication throughout study . 5 . FTLD Modified Hachinski score ≤ 3 . ( Knopman et al. , 2008 ) This modify Hachinski include focal neurological sign , symptom pseudobulbar affect question , give prominence three CBS/PSP . 6 . MMSE ≥ 15 Visit 1 . 7 . Written inform consent provide subject caregiver fluent English speaker . 8 . Subject resides outside skilled nursing facility dementia care facility . Residence assist live facility allow . 9 . If subject receive levodopa/carbidopa , dopamine agonist , COMT inhibitor Parkinson 's medication dose must stable least 120 day prior Visit 1 must remain stable duration study . 10 . Able tolerate MRI scan screening without use sedation . 11 . Able ambulate without assistance . 1 . Insufficient fluency local language complete neuropsychological functional assessment . 2 . A diagnosis Amyotrophic Lateral Sclerosis motor neuron disease . 3 . Any following : Abrupt onset symptom define inclusion criterion 1 associated ictal event , Head trauma related onset symptom define inclusion criterion 1 , Severe amnesia within 6 month symptom define inclusion criterion 1 , Cerebellar ataxia , Choreoathetosis , Early , symptomatic autonomic dysfunction , Tremor rest . 4 . History significant neurological psychiatric disorder include , limited , Alzheimer 's disease , dementia Lewy body , Prion disease , stroke , Parkinson 's disease , psychotic disorder , severe bipolar unipolar depression , seizure disorder , tumor spaceoccupying lesion , head injury loss consciousness within past 20 year temporally related onset symptom . 5 . Within 4 week screen course study , concurrent treatment memantine ( stable dose memantine , great 6 month allow ) , acetylcholinesterase inhibitor , antipsychotic agent mood stabilizer ( valproate , lithium , etc . ) benzodiazepine ( temazepam zolpidem ) . 6 . Treatment lithium , methylene blue , tramiprosate , ketone body , Dimebon putative diseasemodifying agent direct tau within 90 day screen . 7 . A history alcohol substance abuse within 1 year prior screen deem clinically significant site investigator . 8 . Any malignancy ( nonmetastatic basal cell carcinoma skin ) within 5 year Visit 1 current clinically significant hematological , endocrine , cardiovascular , renal , hepatic , gastrointestinal , neurological disease . For noncancer condition , condition stable least past year judge site investigator interfere patient 's participation study , patient may include . 9 . Clinically significant lab abnormality screen , include creatinine ≥ 2.5 mg/dL , vitamin B12 laboratory normal reference range , TSH laboratory normal reference range . 10 . Systolic blood pressure great 180 less 90 mm Hg . Diastolic blood pressure great 105 less 50 mm Hg . 11 . ECG abnormal screen judge clinically significant site investigator . 12 . Treatment investigational drug device participation investigational drug study within 60 day screen . 13 . Known history serum plasma progranulin level &lt; 110.9 ng/mL . 14 . Known presence know diseaseassociated mutation TDP43 , PGRN , CHMPB2 VCP gene FTLD causative gene associate underlying tau pathology ( eg . Chr . 9 associated FTD ) . 15 . History deep brain stimulator surgery sham surgery DBS clinical trial . 16 . History early , prominent REM behavior disorder . 17 . Women childbearing potential use least two form medically recognize contraception . 18 . An employee relative employee Allon Therapeutics 19 . Significant anatomical nasal abnormality ( e.g. , septal deviation obstruct airflow least one nostril septal perforation ) history nasal turbinate surgery . 20 . History clinically significant medical condition would interfere subject 's ability comply study instruction , would place subject increase risk , might confound interpretation study result . 21 . Contraindication MRI examination reason ( eg. , severe claustrophobia , ferromagnetic metal body , etc. ) . 22 . Structural abnormality MRI within 2 year baseline precludes diagnosis PSP , CBS PNFA , cortical infarct brain region might account subject 's symptom . 23 . In subject receive antiParkinson 's Disease medication time screening , opinion investigator substantial worsen motor sign symptom compare normal function follow overnight withdrawal antiParkinson medication . 24 . Subject willing attempt LP .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Frontotemporal Dementia</keyword>
	<keyword>Corticobasal Degeneration</keyword>
	<keyword>Progressive Nonfluent Aphasia</keyword>
	<keyword>Progressive Supranuclear Palsy</keyword>
	<keyword>FTLD</keyword>
	<keyword>FTD</keyword>
	<keyword>PNFA</keyword>
	<keyword>CBD</keyword>
	<keyword>PSP</keyword>
	<keyword>Predicted tauopathies , include :</keyword>
	<keyword>Progressive Supranuclear Palsy ( PSP )</keyword>
	<keyword>( CBS )</keyword>
	<keyword>Progressive Nonfluent Aphasia ( PNFA )</keyword>
</DOC>